Hila Karah - DarioHealth Corp Director
DRIO Stock | USD 1.52 0.03 2.01% |
Director
Ms. Hila Karah is Independent Director of the Company. Ms. Karah is an independent business consultant and an investor in several hightech, biotech and internet companies. From 2006 to 2013, she served as a partner and Chief Investment Officer of Eurotrust Ltd., a family office. From 2002 to 2005, she served as a research analyst at Perceptive Life Sciences Ltd., a New Yorkbased hedge fund. Prior to that, Ms. Karah served as research analyst at Oracle Partners Ltd., a health carefocused hedge fund. Ms. Karah has served as a director in several private and public companies including Intec Pharma, since 2009 and Cyren Ltd since 2008 since 2014.
Age | 47 |
Tenure | 10 years |
Address | 18 West 18th Street, New York, NY, United States, 10011 |
Phone | 833 914 3796 |
Web | https://www.dariohealth.com |
DarioHealth Corp Management Efficiency
The company has return on total asset (ROA) of (0.2737) % which means that it has lost $0.2737 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7359) %, meaning that it created substantial loss on money invested by shareholders. DarioHealth Corp's management efficiency ratios could be used to measure how well DarioHealth Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to -0.54. In addition to that, Return On Assets is likely to drop to -0.49. At this time, DarioHealth Corp's Fixed Asset Turnover is very stable compared to the past year. As of the 28th of March 2024, Asset Turnover is likely to grow to 0.39, while Non Currrent Assets Other are likely to drop about 86 K.Similar Executives
Showing other executives | DIRECTOR Age | ||
Dipchand Nishar | Guardant Health | N/A | |
Richelle Parham | Laboratory | 53 | |
Donna Shalala | Mednax Inc | 75 | |
Robert Williams | Laboratory | 72 | |
Donna Zarcone | Cigna Corp | 63 | |
Mark McClellan | Cigna Corp | 57 | |
George Kurian | Cigna Corp | 54 | |
Pascal Goldschmidt | Mednax Inc | 65 | |
Garheng Kong | Laboratory | 45 | |
Michelle Gass | Cigna Corp | 47 | |
Michael Fernandez | Mednax Inc | 66 | |
Aaref Hilaly | Guardant Health | 46 | |
Stanley Meresman | Guardant Health | 71 | |
JeanLuc Belingard | Laboratory | 72 | |
Manuel Kadre | Mednax Inc | 54 | |
Waldemar Carlo | Mednax Inc | 67 | |
Kimberly Ross | Cigna Corp | 56 | |
Gary Gilliland | Laboratory | 63 | |
William Zollars | Cigna Corp | 70 | |
Roman Martinez | Cigna Corp | 71 | |
Ian Clark | Guardant Health | 57 |
Management Performance
Return On Equity | -0.74 | ||||
Return On Asset | -0.27 |
DarioHealth Corp Leadership Team
Elected by the shareholders, the DarioHealth Corp's board of directors comprises two types of representatives: DarioHealth Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DarioHealth. The board's role is to monitor DarioHealth Corp's management team and ensure that shareholders' interests are well served. DarioHealth Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DarioHealth Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Glen Moller, Director | ||
Josh Fischer, Senior Compliance | ||
Dov Oppenheim, CoFounder Chief | ||
Rami Yehudiha, Director | ||
Hila Karah, Director | ||
Richard Anderson, President | ||
Claudia Levi, Content Manager | ||
Jean Muyl, Head America | ||
Zvi David, Treasurer CFO | ||
Yalon Farhi, Director | ||
Erez Raphael, Chairman, CEO and Pres | ||
Ori Zanco, Director | ||
Mary Mooney, Vice Marketing | ||
Limor Drezner, Chief Officer | ||
Dennis McGrath, Director | ||
Olivier Jarry, President and Chief Commercial Officer | ||
Malcolm Hoenlein, Independent Director | ||
Richard Stone, Independent Director | ||
Tomer BenKiki, Chief Officer | ||
Brian Harrigan, Senior Sales | ||
Yossi Bahagon, Director | ||
Yoav Shaked, Chairman of the Board | ||
Dror Bacher, Chief Officer | ||
Zvi BenDavid, CFO, Treasurer, Secretary | ||
Allen Kamer, Director | ||
Omar MD, Chief Officer |
DarioHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DarioHealth Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.74 | ||||
Return On Asset | -0.27 | ||||
Profit Margin | (2.45) % | ||||
Operating Margin | (4.42) % | ||||
Current Valuation | 28.14 M | ||||
Shares Outstanding | 27.79 M | ||||
Shares Owned By Insiders | 17.17 % | ||||
Shares Owned By Institutions | 31.86 % | ||||
Number Of Shares Shorted | 1.34 M | ||||
Price To Earning | (2.30) X |
Pair Trading with DarioHealth Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DarioHealth Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DarioHealth Corp will appreciate offsetting losses from the drop in the long position's value.Moving together with DarioHealth Stock
0.85 | MMSI | Merit Medical Systems Financial Report 24th of April 2024 | PairCorr |
Moving against DarioHealth Stock
0.48 | FEMY | Femasys Report 4th of April 2024 | PairCorr |
0.46 | CVS | CVS Health Corp Financial Report 1st of May 2024 | PairCorr |
0.42 | NVNO | EnVVeno Medical Corp Financial Report 6th of May 2024 | PairCorr |
The ability to find closely correlated positions to DarioHealth Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DarioHealth Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DarioHealth Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DarioHealth Corp to buy it.
The correlation of DarioHealth Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DarioHealth Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DarioHealth Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DarioHealth Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DarioHealth Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in DarioHealth Stock, please use our How to Invest in DarioHealth Corp guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for DarioHealth Stock analysis
When running DarioHealth Corp's price analysis, check to measure DarioHealth Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DarioHealth Corp is operating at the current time. Most of DarioHealth Corp's value examination focuses on studying past and present price action to predict the probability of DarioHealth Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DarioHealth Corp's price. Additionally, you may evaluate how the addition of DarioHealth Corp to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is DarioHealth Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DarioHealth Corp. If investors know DarioHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DarioHealth Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.852 | Quarterly Revenue Growth (0.47) | Return On Assets (0.27) | Return On Equity (0.74) |
The market value of DarioHealth Corp is measured differently than its book value, which is the value of DarioHealth that is recorded on the company's balance sheet. Investors also form their own opinion of DarioHealth Corp's value that differs from its market value or its book value, called intrinsic value, which is DarioHealth Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DarioHealth Corp's market value can be influenced by many factors that don't directly affect DarioHealth Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DarioHealth Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if DarioHealth Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DarioHealth Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.